

# Improving Cardiovascular Outcomes in T2DM:

## Personalizing Antihyperglycemic Therapy



The **Ohio Academy of Family Physicians** cordially invites you to attend a CME-certified, MOC-eligible virtual event entitled, **Improving Cardiovascular Outcomes in T2DM: Personalizing Antihyperglycemic Therapy**, held live online! The T2DM program will familiarize physicians with the pathophysiology of CVD in T2DM, results of cardiovascular outcomes trials of antihyperglycemics, and recommendations from several societies regarding the use of these agents in patients with T2DM who have or are at risk for CVD.

**Date:** Tuesday, November 9, 2021  
**Time:** 3:00 PM - 4:00 PM Eastern Time  
**Location:** Live Online!

**For full accreditation information and to register, visit:**

<https://www.rockpointe.com/OhioAFPRegistration>

**Suggested Browsers:** Apple Safari, Google Chrome, or Mozilla Firefox

### PROGRAM FACULTY



**Eugene E. Wright, Jr., MD**  
Medical Director, Performance Improvement  
Charlotte AHEC  
Charlotte, NC



**Jay H. Shubrook, DO, FACOFP, FAAFP**  
Professor, Primary Care Department  
Director of Clinical Research and Diabetes Services  
Touro University California  
College of Osteopathic Medicine  
Vallejo, CA

**PHYSICIAN ACCREDITATION STATEMENT** - This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

**PHYSICIAN CREDIT DESIGNATION STATEMENT** – The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**AAFP PHYSICIAN CREDIT DESIGNATION STATEMENT** – The AAFP has reviewed *Improving Cardiovascular Outcomes in T2DM: Personalizing Antihyperglycemic Therapy*, and deemed it acceptable for AAFP credit. Term of approval is from 06/01/2021 to 12/31/2021. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**ABIM MOC RECOGNITION STATEMENT** – Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you **MUST** pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

**For further info:** <https://www.aoeconsulting.com/cme-news-item/abim-moc-assessment-recognition-program-guide/>

**MIPS CREDIT DESIGNATION STATEMENT** - Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA\_PSPA\_28) for the Merit-based Incentive Payment Program (MIPS).

**FEE AND RECEIVING CME CREDIT AND MOC POINTS** – There is no fee for this activity. To receive credit, participants must register, view the live CME activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. Participants are allowed to take the post-test multiple times.

Disclosures will be made known to participants before the activity.

Jointly provided by the Potomac Center for Medical Education and Rockpointe.

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc. and Novo Nordisk.